SequelSEC

VERU INC. VERU

Pharmaceutical Preparations · CIK 0000863894 · Fiscal year ends 0930

Revenue
$16.89M
Fiscal year ended 2024-09-30
Operating income
-$36.17M
Fiscal year ended 2024-09-30
Free cash flow
-$21.84M
Fiscal year ended 2024-09-30

VERU INC. (VERU) reported revenue of $16.89M and net income of -$37.80M for the fiscal year ended 2024-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from VERU INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

VERU INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-09-30
Revenue$16.89M
Cost of revenue$11.03M
Gross profit$5.85M
Operating income-$36.17M
Net income-$37.80M
Research & development$12.78M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrative$31.18M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

VERU INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-09-30
Cash & equivalents$24.92M
Total assets$60.42M
Current assets$35.22M
Total liabilities$28.10M
Current liabilities$11.87M
Total equity incl. NCI$32.32M
Temporary (mezzanine) equityUnavailable
Inventory$4.14M
Accounts receivable$3.96M
Goodwill$6.88M
Long-term debtUnavailable
Accounts payable$2.26M

Cash flow

VERU INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-09-30
Operating cash flow-$21.68M
Capital expenditures$158.32K
Investing cash flow$146.21K
Financing cash flow$36.83M
Net change in cash$15.29M
Stock-based compensation$13.64M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$268.18K

Derived

VERU INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-09-30
Free cash flow-$21.84M
Gross margin34.7%
Operating margin-214.2%
FCF margin-129.3%
SBC / revenue80.8%
Current ratio2.97x
Revenue YoY growth3.6%
Net margin-223.9%
R&D / revenue75.7%
CapEx / revenue0.9%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VERU in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-Q · Filed 2026-02-11View SEC filing
10-K · Filed 2025-12-17View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.